Drug Trial Radar · NCT02452372
A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
Last checked: Nov 20, 2026Latest source record: Jun 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
May 6, 2015
Primary completion
Sep 6, 2017
Study completion Sep 6, 2017
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- May 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of givosiran (ALN-AS1) in AIP patients as well as to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of ALN-AS1 in AIP patients.
Conditions
- Acute Intermittent Porphyria
Interventions
givosiran (ALN-AS1)Drug
Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection
Sterile Normal Saline (0.9% NaCl)Drug
calculated volume to match active comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety of givosiran evaluated by the proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), and AEs leading to study drug discontinuationTime frame: Part A (SAD phase): through day 42; Part B (MAD) phase: through Day 70; Part C (MD) phase: through Day 168
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Birmingham, Alabama
Clinical Trial Site
San Francisco, California
Clinical Trial Site
New York, New York
Clinical Trial Site
Galveston, Texas
Clinical Trial Site
Stockholm, Sweden
Clinical Trial Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.